Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 15, Issue 10, Pages 1183-1198
Publisher
Informa UK Limited
Online
2015-09-25
DOI
10.1586/14737140.2015.1081816
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
- (2015) S Ohkawa et al. BRITISH JOURNAL OF CANCER
- Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer
- (2015) In Gyu Hwang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
- (2015) S. Kordes et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Continuous, low-dose capecitabine for patients with recurrent colorectal cancer
- (2015) Adriana Romiti et al. MEDICAL ONCOLOGY
- Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma
- (2014) D. Propper et al. ANNALS OF ONCOLOGY
- Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study
- (2014) R. Buzzoni et al. ANNALS OF ONCOLOGY
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
- (2014) D.J. Renouf et al. EUROPEAN JOURNAL OF CANCER
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
- (2014) David Malka et al. LANCET ONCOLOGY
- Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
- (2014) Jasmine Miger et al. MEDICAL ONCOLOGY
- S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: A Randomized, Open-Label, Multicenter, Phase II Study
- (2014) F. Ge et al. ONCOLOGIST
- A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
- (2014) D. Li et al. PANCREATOLOGY
- A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
- (2013) A H Ko et al. BRITISH JOURNAL OF CANCER
- Metronomic chemotherapy for cancer treatment: a decade of clinical studies
- (2013) Adriana Romiti et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer
- (2013) Naminatsu Takahara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin
- (2013) Shengli He et al. JOURNAL OF CHEMOTHERAPY
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
- (2013) Hideki Ueno et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer
- (2013) Sheng-bin Shi et al. PANCREATOLOGY
- Improvement of prognosis for unresectable biliary tract cancer
- (2013) Takashi Sasaki WORLD JOURNAL OF GASTROENTEROLOGY
- A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
- (2012) Peter J. Hosein et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
- (2012) Giacomo Allegrini et al. ANGIOGENESIS
- Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer
- (2012) Naminatsu Takahara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
- (2012) Alberto Zaniboni et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study
- (2012) Thomas Walter et al. EUROPEAN JOURNAL OF CANCER
- Treatment options for advanced pancreatic cancer: a review
- (2012) Rahma Warsame et al. Expert Review of Anticancer Therapy
- Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
- (2012) Katharina Elisabeth Tschoep-Lechner et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
- (2012) Anne M. Horgan et al. JOURNAL OF CLINICAL ONCOLOGY
- The biliary tree—a reservoir of multipotent stem cells
- (2012) Vincenzo Cardinale et al. Nature Reviews Gastroenterology & Hepatology
- Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer
- (2012) Kyu-Hyoung Lim et al. ONCOLOGY
- FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts
- (2012) Cindy Neuzillet WORLD JOURNAL OF GASTROENTEROLOGY
- Tumors of ampulla of Vater: A case series and review of chemotherapy options
- (2012) Adriana Romiti World Journal of Gastrointestinal Oncology
- Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers
- (2011) Kristoffer S. Rohrberg et al. ACTA ONCOLOGICA
- A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma
- (2011) N. Starling et al. ANNALS OF ONCOLOGY
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
- (2011) M Miyamoto et al. BRITISH JOURNAL OF CANCER
- Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
- (2011) Chigusa Morizane et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Salvage Therapy with Mitomycin and Ifosfamide in Patients with Gemcitabine-Resistant Metastatic Pancreatic Cancer: A Phase II Trial
- (2011) Stefano Cereda et al. CHEMOTHERAPY
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
- (2011) Jun Ho Yi et al. EUROPEAN JOURNAL OF CANCER
- Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
- (2011) Shimpei Maeda et al. International Journal of Clinical Oncology
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
- (2011) Jeeyun Lee et al. LANCET ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
- (2011) Elias Assaf et al. ONCOLOGY
- Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer
- (2010) Anna Novarino et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma
- (2010) Vittorio Gebbia et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
- (2010) Igor A. Astsaturov et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
- (2010) Milind M Javle et al. BMC CANCER
- Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial
- (2010) Ourania Katopodis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
- (2010) Kentaro Sudo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
- (2010) Andrew H. Ko et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
- (2010) Benjamin Chuah et al. CANCER SCIENCE
- Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness
- (2010) Sung Yong Oh et al. INVESTIGATIONAL NEW DRUGS
- Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer
- (2010) Takashi Sasaki et al. INVESTIGATIONAL NEW DRUGS
- Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
- (2010) Takashi Sasaki et al. INVESTIGATIONAL NEW DRUGS
- S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure
- (2010) A. Todaka et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study
- (2010) Atul Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
- (2010) E. M. O'Reilly et al. ONCOLOGIST
- Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer
- (2009) Suee Lee et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
- (2009) C Bengala et al. BRITISH JOURNAL OF CANCER
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
- A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
- (2009) Ramesh K. Ramanathan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine
- (2009) Tudor E. Ciuleanu et al. EUROPEAN JOURNAL OF CANCER
- Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers
- (2009) Maria S. Pino et al. ONCOLOGY
- Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
- (2009) Joanna M. Brell et al. ONCOLOGY
- A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer
- (2009) Richard D. Carvajal et al. PANCREATOLOGY
- Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study
- (2009) Uwe Pelzer et al. Oncology Research and Treatment
- PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen as Second-Line Therapy in Patients With Progressive or Recurrent Pancreatic Cancer After Gemcitabine-Containing Chemotherapy
- (2008) M Reni et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer
- (2008) Henry Q. Xiong et al. CANCER
- Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
- (2008) Yoon Jae Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
- (2008) Seong Yoon Yi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
- (2008) Chigusa Morizane et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Douglas B. Evans et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- The anatomic location of pancreatic cancer is a prognostic factor for survival
- (2008) Avo Artinyan et al. HPB
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now